QSimulate has announced an additional round of seed financing, bringing its total funding to date to over $11 million. The company, which focuses on quantum simulation technology for drug discovery, simultaneously announced QUELO v2.3, the latest generation of its quantum-powered simulation platform.
QSimulate’s platform is built on a quantum mechanics approach to molecular modeling, designed to simulate interactions between drugs and proteins at the molecular level. QUELO v2.3 introduces enhanced sampling techniques and capabilities for larger molecules and peptide drugs. The company’s engine is claimed to perform predictive molecular simulations 1,000× faster than traditional methods, achieving results within milliseconds per snapshot.
The new funding will enable QSimulate to scale operations and platform expansion to meet demand from multinational companies, including Google, Mitsui, JT Pharma, and five of the world’s top 20 pharmaceutical companies. Toru Shiozaki, co-founder and CEO of QSimulate, noted that the approach uses quantum mechanics to unlock molecular insights in drug discovery that conventional AI methods cannot reach.
Read the full announcement here.
In GQI Portal
The players behind the news
The team that writes QCR tracks every company, deal and technology in the GQI Factory, GQI's verified database of the quantum industry. Next up: every story linked to its players, coming to QCR's paid plans.
- Players Companies and institutions across the quantum industry, by segment.
- Scorecards How the players compare on hardware, software, funding and more.
Newsletter
QCR Alerts in your inbox
The latest reporting and analysis from Quantum Computing Report. Free, unsubscribe any time.